Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.
The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy.
We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech gems.
-----------------------------------------------------------------------
Get expert legal advisory support for growing your biotech from Osborne Clarke at https://bit.ly/oc-flotbio
----------------------------------------------------------------------
⭐️ ABOUT THE SPEAKER
With many years of experience in big pharma, Pascal had top-level positions at Novartis Oncology. He later served as CEO, and most recently Chairman, of Atara Biotherapeutics. Alongside his Jeito role, he sits on the boards of companies including Ipsen, Medincell, Catalym, Xylocor and CDR-Life.
🔗 LINKS MENTIONED
📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/pascal-touchon-jeito/
💸 DONATE
We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🫶 FOLLOW US
🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.
⏰ TIMESTAMPS
